Subcutaneous tocilizumab in chronic active humoral kidney graft rejection

Nefrologia (Engl Ed). 2022 Jul-Aug;42(4):498-500. doi: 10.1016/j.nefroe.2022.06.004.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antibodies, Monoclonal, Humanized* / therapeutic use
  • Graft Rejection* / drug therapy
  • Humans
  • Kidney

Substances

  • tocilizumab
  • Antibodies, Monoclonal, Humanized